Oncophage Effect In Subgroup Supports Continued Development, Firm Says
Executive Summary
Antigenics is seeing salvation for its Oncophage cancer vaccine based on signs of a clinically significant improvement in a subgroup of patients with a better prognosis in its Phase III renal cell carcinoma trial
You may also be interested in...
Sanofi Looks To Enter Cancer Vaccine Field With TroVax Acquisition
A collaboration between Sanofi-Aventis and Oxford BioMedica in the area of therapeutic cancer vaccines could extend beyond the development of TroVax to second-generation therapeutic vaccines combining technology from both companies, Sanofi Senior VP-Head of Oncology Allain Herrera said
Sanofi Looks To Enter Cancer Vaccine Field With TroVax Acquisition
A collaboration between Sanofi-Aventis and Oxford BioMedica in the area of therapeutic cancer vaccines could extend beyond the development of TroVax to second-generation therapeutic vaccines combining technology from both companies, Sanofi Senior VP-Head of Oncology Allain Herrera said
Lung Cancer Immunotherapies Show Promise, But New Directions Needed
Results from two cancer vaccine studies suggest that lung cancer patients may benefit from immunotherapy, David Carbone (Vanderbilt-Ingram Cancer Center) concluded at the American Society of Clinical Oncology's annual meeting June 4 in Atlanta